drugset
drugset / Trial / NCT05336721

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

NCT05336721 ↗

Phase 2 Terminated 9 enrolled Chipscreen Biosciences, Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the preliminary efficacy and safety of chiauranib in combine with capecitabine in advanced triple-negative breast cancer failed to prior anthracyclines and taxanes therapy

Timeline

Start
2021-11-05
Primary completion
2024-10-31
Completion
2024-11-05

Outcome

Outcome not reported

Stopped (Enrollment): “During the enrollment period of this project, due to the increasing proportion of patients receiving capecitabine adjuvant therapy and the large number of trials competing for the same number of lines in various centers”

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 —
Subject IBCASERTIB Small molecule 25 mg Oral
Subject IBCASERTIB Small molecule 35 mg Oral
Subject IBCASERTIB Small molecule 50 mg Oral

Indications

triple-negative breast carcinoma